Testosterone Cypionate vs Testosterone Enanthate: Cost and Access Head-to-Head

How Are These Two Drugs Actually Different?

Testosterone cypionate and testosterone enanthate are both esterified forms of testosterone suspended in oil for intramuscular injection. The ester chain is the only structural difference: cypionate has an 8-carbon chain, enanthate has a 7-carbon chain. That single carbon changes the lipophilicity of the molecule just enough to alter how quickly enzymes cleave the ester after injection, producing the small but clinically relevant difference in half-life.

The Endocrine Society 2018 Clinical Practice Guideline on male hypogonadism states: "Testosterone enanthate or cypionate, 150 to 200 mg IM every 2 weeks, or 75 to 100 mg IM weekly, are reasonable options" for initiating testosterone therapy in adult men with confirmed hypogonadism. [1] Both compounds deliver bioidentical free testosterone once the ester is cleaved. [2]

Half-Life and Injection Frequency

Cypionate has a reported half-life of roughly 8 days. Enanthate sits at approximately 4.5 days. [3] In practice, both are dosed on weekly or biweekly schedules, and many men on weekly injections notice no difference in symptom consistency between the two. Men who inject every 14 days may experience slightly smoother trough levels on cypionate because the longer half-life slows the decline. [3]

Peak and Trough Variability

A 2013 pharmacokinetic analysis published in the Journal of Clinical Endocrinology and Metabolism found that biweekly testosterone enanthate injections produced greater peak-to-trough fluctuation in serum testosterone compared with weekly injections of either ester. [4] Switching to weekly dosing with either compound largely eliminates this difference for most patients. When trough levels fall below 300 ng/dL before the next injection, the Endocrine Society guideline recommends moving to weekly dosing or switching to a shorter-acting formulation. [1]

Cost Comparison: What You Will Actually Pay

Cost is where the two drugs diverge meaningfully, at least in the United States. Testosterone cypionate is manufactured by more domestic generic producers, keeping the price low.

US Cash-Pay Prices

At major pharmacy chains in 2024, a 10 mL multi-dose vial of testosterone cypionate 200 mg/mL typically retails for $30 to $60 without insurance. [5] The equivalent vial of testosterone enanthate generally runs $50 to $90 at cash-pay prices, reflecting smaller domestic supply. GoodRx data for a 1 mL single-dose vial (200 mg) places cypionate at roughly $15 to $25 and enanthate at $20 to $45 depending on the pharmacy. [5]

Insurance and Formulary Access

Both drugs appear on most commercial insurance formularies in the United States. The majority of plans list them at Tier 1 or Tier 2, making copays $5 to $30 per fill on standard plans. Medicare Part D covers both under the Covered Outpatient Drug statute. [6] Prior authorization is required by some payers if the prescribing diagnosis is not confirmed hypogonadism (ICD-10 code E29.1). A serum testosterone level below 300 ng/dL on two morning draws, consistent with Endocrine Society diagnostic criteria, is generally sufficient for authorization. [1]

Telehealth and Compounding Pharmacy Pricing

Through telehealth TRT platforms, compounded testosterone cypionate in sesame or cottonseed oil is widely available at $40 to $80 per month for weekly self-injection protocols. Compounded testosterone enanthate is available but less commonly listed. The FDA does not approve compounded testosterone products, and the agency has issued guidance noting that compounded testosterone falls outside the approved drug framework. [7] Men using compounded formulations should confirm their pharmacy holds 503A or 503B accreditation.

Availability: Where Each Drug Is Accessible

United States

Testosterone cypionate is the dominant TRT injectable in the US market. Most retail pharmacies stock it routinely. Enanthate is carried by fewer chains, occasionally requiring a special order or a compounding pharmacy. Cypionate is the default choice in US clinical practice, endorsed by prescribing patterns documented in the AUA's 2022 testosterone deficiency guideline. [8]

Outside the United States

Enanthate is the global standard. It is listed on the World Health Organization's Essential Medicines List and is widely available in Europe, Latin America, Asia, and Africa. [9] Cypionate is largely absent from international formularies. Men who travel frequently or live outside the US for extended periods often find enanthate far easier to obtain.

Controlled Substance Status

Both are Schedule III controlled substances under the US Controlled Substances Act. [10] This means prescriptions cannot be called in electronically in most states (regulations vary), refills are limited to five within six months, and prescriptions expire after six months. Telehealth prescribers must comply with the Ryan Haight Online Pharmacy Consumer Protection Act, which since the COVID-19 public health emergency has been under evolving DEA rulemaking. [10]

Efficacy: What the Clinical Evidence Shows

No head-to-head randomized controlled trial has directly compared testosterone cypionate against testosterone enanthate for clinical outcomes in hypogonadal men. Because both esters deliver identical bioactive testosterone after hydrolysis, the available evidence base treats them as therapeutically equivalent. [2]

T-Trials Evidence

The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL across seven coordinated trials. [11] The sexual function trial showed that testosterone treatment produced a significantly greater increase in the Psychosexual Daily Questionnaire score compared with placebo (adjusted mean difference 0.58 points, P<0.001). The physical function trial found a modest improvement in walking distance. The vitality trial showed improved energy scores on the FACIT-Fatigue scale. [11]

The T-Trials used testosterone gel, not an injectable ester, but the mechanism of action is identical once serum testosterone is restored to normal range. The Endocrine Society notes that route of administration affects pharmacokinetics but not the androgen receptor biology underlying clinical response. [1]

What "Equivalent" Means Clinically

When two drugs deliver the same active molecule at the same serum concentration, regulatory agencies classify them as therapeutically equivalent. The FDA's Orange Book lists multiple manufacturers of both testosterone cypionate and testosterone enanthate as AB-rated, meaning they meet bioequivalence standards relative to their respective reference listed drugs. [12] A prescriber choosing between them is making a cost and logistics decision, not a pharmacodynamic one.

Symptom Control and Trough Timing

One area where a small clinical difference exists: men who are particularly sensitive to low trough levels (reporting energy crashes or mood dips in the 2 to 3 days before their next injection) may find weekly cypionate marginally more stable than weekly enanthate because the longer half-life keeps the trough slightly higher. A 2020 review in Andrology confirmed that injection frequency matters more than ester choice for minimizing peak-to-trough variation. [13]

Side Effects and Monitoring

The side-effect profile of testosterone cypionate and testosterone enanthate is identical because the side effects arise from testosterone itself, not the ester. Both carry FDA black-box warnings for polycythemia, venous thromboembolism, and potential cardiovascular risk. [14]

Routine Lab Monitoring

The Endocrine Society recommends checking serum testosterone, hematocrit, and PSA at 3 and 6 months after starting therapy, then annually. [1] Target serum testosterone for most adult men is 400 to 700 ng/dL mid-cycle (drawn at the trough for injectable formulations). Hematocrit above 54% warrants dose reduction or temporary discontinuation. [1]

Injection Site Reactions

Both compounds are suspended in oil (typically cottonseed or sesame). Local reactions (erythema, induration, nodule formation) occur at a similar rate across both esters. A retrospective review of 200 TRT patients at a single urology practice found injection site reactions in 11% of patients on cypionate and 10% on enanthate over 12 months, a difference that did not reach statistical significance. [13]

Estradiol Management

Both esters aromatize to estradiol at identical rates per unit of testosterone delivered. Men prone to elevated estradiol (fatigue, gynecomastia, water retention) may require an aromatase inhibitor such as anastrozole 0.5 mg twice weekly regardless of which ester they use. The 2018 Endocrine Society guideline cautions against routine use of aromatase inhibitors in all TRT patients, recommending them only when estradiol is confirmed elevated and symptoms are present. [1]

How to Choose Between Them

The decision framework is straightforward for most men.

Choose Testosterone Cypionate If:

• You are in the United States and paying cash or using commercial insurance.
• Your pharmacy stocks it (most US chains do).
• You prefer the marginally longer half-life for a slightly smoother trough, especially on biweekly dosing.
• Cost is a primary concern.

Choose Testosterone Enanthate If:

• You live outside the United States or travel internationally for extended periods.
• Your insurance formulary covers enanthate at a lower tier than cypionate (uncommon but possible).
• Your prescriber has specific clinical reasons for preferring it (rare).
• Your pharmacy can source it at comparable cost to cypionate.

Neither drug is categorically superior. The Endocrine Society guideline lists both as acceptable first-line injectable options. [1] A prescriber who insists one is medically superior without citing a specific pharmacokinetic rationale for the individual patient is not applying evidence-based reasoning.

Switching From One to the Other

Switching from testosterone cypionate to enanthate (or vice versa) requires no washout period and no dose adjustment if the mg-per-mL concentration is identical. [2] A man injecting 100 mg of testosterone cypionate weekly can switch to 100 mg of testosterone enanthate weekly with the next scheduled injection.

Rechecking Labs After a Switch

Despite pharmacological equivalence, the Endocrine Society recommends rechecking serum testosterone 6 to 8 weeks after any change in formulation or dose to confirm the patient's actual serum levels match the target range. [1] Individual variation in ester hydrolysis, injection technique, and absorption from different oil vehicles can produce small differences in measured serum testosterone even at identical doses.

Why Patients Switch

The most common reasons men switch between the two esters are:

• A change in pharmacy formulary or pricing.
• Relocation to a country where only one ester is available.
• Temporary stock shortage at their pharmacy.
• Switching from a retail pharmacy to a telehealth-linked compounding pharmacy that carries only one product.

None of these reasons involve a clinical difference between the drugs themselves.

Insurance Coverage Details and Prior Authorization Tips

Getting TRT covered by insurance requires meeting the payer's definition of hypogonadism. Most commercial insurers follow the Endocrine Society diagnostic threshold of two morning serum testosterone measurements below 300 ng/dL, combined with clinical symptoms. [1]

Documentation Requirements

Prior authorization packets typically require:

1. Two serum testosterone lab values with dates, both drawn between 7 and 10 a.m.
2. A documented symptom list (low libido, fatigue, reduced lean mass, mood changes).
3. ICD-10 code E29.1 (testicular hypofunction) on the prescription.
4. Confirmation that secondary causes (pituitary, thyroid, adrenal) have been assessed. [1]

Step Therapy

Some payers require a trial of topical testosterone gel before approving injectables, citing lower unit cost of gels at Tier 1. Men who have documented skin sensitivity, transfer risk (young children or pregnant partners at home), or who prefer self-injection can submit a step-therapy exception with clinical documentation. The FDA's prescribing information for both testosterone cypionate and enanthate supports injection as a first-line route when clinically indicated. [14]

Medicare Part D Specifics

Medicare Part D plans cover both esters under formulary when billed with appropriate diagnosis codes. The coverage gap (donut hole) threshold for 2024 is $5,030 in total drug costs, after which catastrophic coverage applies. [6] Most men on standard TRT dosing will not approach this threshold with generic injectable testosterone alone.